/

Empresas

Zy

No verificado

Zymeworks Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasMedicina Salud Bienestar

31 Comunicados de prensa

Ver todos los comunicados de prensa

17/11/2025

Biotecnología

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Fuente

Editor

1.00

0

17/11/2025

Biotecnología

Anuncios breves

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Fuente

Editor

1.00

0

17/11/2025

Biotecnología

Medicina Salud Bienestar

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Fuente

Editor

1.00

0

23/10/2025

Biotecnología

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Fuente

Editor

1.00

0

13/10/2025

Biotecnología

Medicina Salud Bienestar

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Fuente

Editor

1.00

0

09/10/2025

Biotecnología

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Fuente

Editor

1.00

0

02/09/2025

Biotecnología

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Fuente

Editor

1.00

0

19/08/2025

Biotecnología

Zymeworks Announces Participation in Upcoming Investor Conferences

Fuente

Editor

1.00

0

11/08/2025

Biotecnología

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Fuente

Editor

1.00

0

28/07/2025

Biotecnología

Medicina Salud Bienestar

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0